期刊文献+

四联疗法治疗难治性消化溃疡患者的临床疗效观察 被引量:3

Observation of clinical effect by quadruple therapy in the treatment of refractory peptic ulcer patients
下载PDF
导出
摘要 目的探讨四联疗法治疗难治性消化溃疡患者的临床疗效。方法 112例难治性消化溃疡患者,将其按照治疗措施的不同分为观察组56例和对照组56例,观察组采用四联疗法治疗,对照组患者采取三联疗法治疗,对比两组患者的治疗效果和幽门螺杆菌根除率。结果观察组治疗总有效率为98.21%,幽门螺杆菌根除率为94.64%;对照组治疗总有效率为62.50%,幽门螺杆菌根除率为46.43%。两组比较差异均有统计学意义(P<0.05)。结论四联疗法治疗难治性消化溃疡患者的临床疗效显著,且幽门螺杆菌的根除率较高,值得在临床上推广使用。 Objective To investigate clinical effect by quadruple therapy in the treatment of refractory peptic ulcer patients.Methods A total of 112 patients with refractory peptic ulcer were divided by different treatment measures into observation group with 56 cases and control group with 56 cases. The observation group received quadruple therapy, and the control group received triple therapy. Curative effects and eradication rate of helicobacter pylori were compared between the two groups.Results The observation group had total effective rate as 98.21% and eradication rate of helicobacter pylori as 94.64%. The total effective rate was 62.50% in the control group, and the eradication rate of helicobacter pylori was 46.43%. The differences between the two groups all had statistical significance (P〈0.05).Conclusion Implement of Quadruple therapy in treating refractory peptic ulcer patients provides precisely clinical effect, along with high eradication rate of helicobacter pylori. This method is worthy of clinical promotion and application.
出处 《中国实用医药》 2015年第35期29-30,共2页 China Practical Medicine
关键词 四联疗法 难治性消化溃疡 临床疗效 Quadruple therapy Refractory peptic ulcer Clinical effect
  • 相关文献

参考文献4

二级参考文献31

  • 1Venerito M, Wex T, Malfertheiner P. Helicobacter pylori related and non-related lesions in the stomach[J ]. Minerva Gastroenterol Dietol, 2011, 57(4): 395.
  • 2Sebekina OV, Trubitsyna IE, Masharova AA, et al. Clinical variants of chronic urticaria associated with Helicobacter pyloft[J]. Eksp Klin Gastroenterol, 2011, (5) : 20.
  • 3Chaturvedi R, de Sahlet T, Cohum LA, et al. Arginine and polyarnines in Helieobacter pylori - induced immune dysregulation and gastric eareinogenesis[J ]. Amino Acids, 2011: [Epub ahead of print].
  • 4Selgrad M, Bomschein J, Malfertheiner P. Guidelines for treatment of Helieobacter pylori in the East and West[J]. Expert Rev Anti Infect Ther, 2011, 9(8) : 581.
  • 5Guo X, Zhao BH, Zhang MX. Risk factors of Helicobaeter pylori infection among adults in northern China[J]. Hepatogastroenterology, 2011, 58(106): 306.
  • 6Luther J, Chey WD, Saad RJ. A clinician's guide to salvage therapy for persistent Helicobacter pylori infection[J]. Hosp Pract (Minneap), 2011, 39(1): 133.
  • 7Felga G, Silva FM, Barbuti RC, et al. Clarithromycin- based triple therapy for Helicobacter pylori treatment in peptic ulcer patients[J]. J Infect Dev Ctries, 2010, 4 (11): 712.
  • 8Haziri A, Juniku- Shkololli A, Gasshi Z, et al. Helieobacter pylori infection and precancerous lesions of the stomach[J]. Med Arh, 2010, 64(4): 248.
  • 9Venerito M, Wex T, Malfertheiner P. Helicobacter pylori related and non-related lesions in the stomach [J] . Minerva Gastroenterol Dietol, 2011, 57 (4) : 395-403.
  • 10Felga G, Si|va FM, Barbuti RC, et al. Clarithromycin-based triple thera- py for Helicobacter pylori treatment in peptic ulcer patients [J] . J Infect Dev Ctries, 2010, 4 (11) : 712-716.

共引文献44

同被引文献13

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部